Market exclusivity after a prescription to nonprescription drug switch: Striking the right balance between innovation and competition

Food and Drug Law Journal

Volumn 54, Issue 2, 1999, Pages 243-244

  Kraushaar, Kevin J ^a  

^a Consum Hlthcare Prod Association ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; NON PRESCRIPTION DRUG;

CONFERENCE PAPER; CONSUMER; DRUG COST; DRUG LABELING; DRUG LEGISLATION; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; MEDICAL FEE;

EID: 0032813579     PISSN: 1064590X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (4)

1. Pub. L. No. 98-417, 98 Stat. 1585 (1984) (codified in sections of 15 U.S.C. (1994), 21 U.S.C. (1994), 28 U.S.C. (1994), and 35 U.S.C. (1994)).
2. Based on data compiled by the Consumer Healthcare Products Association (CHPA).
3. Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as amended 21 U.S.C. §§ 301 et seq. (1994)).
4. For a more detailed analysis of whether a prescription drug is "switchable," see R. William Soller, OTCness, 32 DRUG INFO. J. 555 (1998).